IMI at AD/PD 2015

IMI and its Alzheimer’s disease projects AETIONOMY, EMIF and EPAD held a symposium entitled ‘From data to mechanisms to therapies for patients' at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD 2015) in Nice, France on Thursday 19 March 2015.

About the session - From data to mechanisms to therapies for patients

It is increasingly recognised that collaboration, between industry, academia, patient groups, regulators and others, is essential if we are to take on the biggest challenges in medical research. This session spotlit how public-private partnerships on both sides of the Atlantic are harnessing the power of collaboration to drive progress in diverse aspects of Alzheimer’s disease research and drug development. In Europe, the AETIONOMY, EMIF and EPAD projects form the Innovative Medicines Initiative (IMI) Alzheimer’s Disease Platform, a coherent research platform that will ensure ideas are shared and rapidly turned from data into mechanisms and, ultimately, new therapies for patients. The three IMI projects also work closely with related initiatives, including the UK Dementias Platform and the Global Alzheimer’s Platform.
 

Agenda & presentations
 

• Welcome
  Dr. Elisabetta Vaudano, Principal Scientific Manager, Innovative Medicine Initiative (IMI)
• AETIONOMY: A big data approach for the generation of a mechanism-based taxonomy for AD and PD
  Professor Martin Hofmann-Apitius, Head of the Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) & Academic Coordinator, AETIONOMY
• The IMI-European Medical Information Framework (EMIF); repurposing and connecting data for Alzheimer’s disease and beyond
  Professor Simon Lovestone, Professor of Translational Neuroscience, Department of Psychiatry, University of Oxford & Co-coordinator, EMIF
• Dementias Platform UK (DPUK): a global resource for the dementias
  Professor John Gallacher, Director MRC UK Dementias Platform, Institute of Primary Care & Public Health, Cardiff University School of Medicine
• ‘Mind the Gap’: new initiatives from across the pond
  Professor Howard Feldman, Head UBC Division of Neurology, Director Clinic for Alzheimer Disease & Related Disorders, UBC Hospital, University of British Columbia
• The power of partnership: the IMI research platform on Alzheimer's Disease and Neurodegeneration - an industry perspective
  Dr Luc Truyen Janssen, VP Neuroscience External Affairs & Chair, JNJ, Global Fight Against Alzheimer's Disease, Johnson & Johnson
• The European Prevention of Alzheimer’s Dementia (EPAD) programme: Clinical and scientific need and early progress
  Professor Craig W. Ritchie, Professor of Psychiatry of Ageing, Centre for Clinical Brain Sciences/Department of Psychiatry, University of Edinburgh & Coordinator, EPAD